2-[4-(4-fluorophenyl)piperazin-1-yl]-6-methylpyrimidin-4(3H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[4-(4-fluorophenyl)piperazin-1-yl]-6-methylpyrimidin-4(3H)-one
• 英文别名: 2-[4-(4-fluorophenyl)piperazin-1-yl]-4-methyl-1H-pyrimidin-6-one
• 化学式: C₁₅H₁₇FN₄O
• mdl: MFCD06753114
• 分子量: 288.32
• InChiKey: AGOINTKVGRVJJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Methods of mammalian retinal stem cell production and applications
  申请人：The Regents of the University of California

  公开号：US10220117B2

  公开（公告）日：2019-03-05

  The invention provides an in vitro method for producing isolated mammalian primitive retinal stem cells (pRSCs) comprising: (a) culturing isolated embryonic stem cells (ESCs) from a mammal in a cell culture medium that is free of feeder cells, feeder-conditioned medium or serum so as to produce and grow a culture of the isolated ESCs; and (b) contacting the culture of the isolated ESCs so grown with one or more of an inhibitor for Wnt or TGF-β/BMP signaling so as to differentiate the isolated ESCs of (a) into primitive retinal stem cells thereby producing isolated mammalian pRSCs.

  本发明提供了一种生产分离的哺乳动物原始视网膜干细胞（pRSCs）的体外方法，包括(a) 在不含饲养细胞、饲养调节培养基或血清的细胞培养基中培养来自哺乳动物的分离胚胎干细胞（ESCs），以产生和生长分离的ESCs培养物；以及 (b) 用一种或多种Wnt或TGF-β/BMP信号转导抑制剂与如此生长的分离ESCs培养物接触，以使(a)中的分离ESCs分化为原始视网膜干细胞，从而产生分离的哺乳动物pRSCs。
• Anti-CD70 combination therapy
  申请人：University of Bern

  公开号：US10391168B1

  公开（公告）日：2019-08-27

  Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.

  本文提供了使用WNT信号通路抑制剂和BCR-ABL1酪氨酸激酶抑制剂的治疗组合来治疗BCR-ABL1相关疾病（如慢性粒细胞白血病）的方法和组合物。
• Methods for treating diseases related to the wnt pathway
  申请人：Sandia Corporation

  公开号：US10624949B1

  公开（公告）日：2020-04-21

  The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway.

  本发明涉及治疗疾病的方法，其中疾病是由 Wnt 信号通路失调引起的。在某些情况下，可以通过施用抑制 Wnt 通路的化合物来治疗疾病。在其他情况下，该方法可选地包括进行全基因组筛选，以确定导致疾病状态降低的一个或多个基因，然后确定这些基因参与Wnt信号通路。
• METHODS OF MAMMALIAN RETINAL STEM CELL PRODUCTION AND APPLICATIONS
  申请人：The Regents of the University of California

  公开号：EP3047017A2

  公开（公告）日：2016-07-27
• COMBINATION THERAPY FOR TREATMENT OF CANCER
  申请人：Oncomed Pharmaceuticals, Inc.

  公开号：EP3185884A1

  公开（公告）日：2017-07-05